Fewer pulmonary exacerbations, hospitalizations with Trikafta: Study
Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) contributed to a reduction in pulmonary exacerbations requiring hospitalization between 2018 and 2022 among children and young adults with cystic fibrosis (CF). That’s according to a recent study in the U.S. that also demonstrated that the proportion of hospitalized CF patients from minority groups,…